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ABSTRACT

Heterotaxy refers to the abnormal arrangement of internal organs in relation to
each other. Model organism studies have shown that functions of more than eighty
genes are required for normal asymmetric left-right organ development. CRELD1 has
been shown to be necessary for proper heart development and mutations in CRELD1
are known to increase risk of cardiac atrioventricular septal defects (AVSD). AVSD
is the most common form of heart defect associated with heterotaxy, and we have
previously shown that some individuals with heterotaxy-related AVSD have
mutations in CRELD1.
Therefore, we propose to examine the CRELD1 gene in a large sample of
patients with heterotaxy syndrome. Our goal was to determine if mutations in
CRELD1 are associated with other manifestations of heterotaxy or if they only
coincide with AVSD. To achieve this aim, a sample size of 126 patients with
heterotaxy collected by Dr. Belmont, Baylor college of Medicine, Texas, with
approximately 66% of the heterotaxy population with different types of heart defects,
were used for this study. Ten exons, promoter regions, and regulatory elements in the
introns of CRELD1 gene were sequenced and analyzed.
In this study three different heterozygous missense mutations in CRELD1 were
identified in three unrelated individuals. These three individuals were diagnosed with
different forms of heart defects in addition to AVSD. All three mutations were
identified in highly conserved regions of CRELD1 possibly altering the CRELD1
properties. This demonstrates that mutations in CRELD1 may increase the
i

susceptibility of AVSD in heterotaxy population. This information can help us to find
factors effecting disease susceptibility in heterotaxy patients since the heart defects are
a complex trait with incomplete penetrance.
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CHAPTER I: INTRODUCTION
1.1-HETEROTAXY AND PHENOTYPIC CHARACTERISTICS
Heterotaxy (hetero meaning ‘other’ and taxy meaning ‘arrangement’) refers
to an abnormal developmental condition characterized by randomized arrangement
of the thoracic and/or abdominal visceral organs, including the heart, lungs, liver,
stomach, and spleen. The organs are either located randomly with respect to the leftright (L-R) axis or to one another. This genetic disorder is characterized by multiple
congenital malformations and complex cardiovascular malformation that is reported
to be the major cause of morbidity and mortality in this population (Table1.1).
Heterotaxy accounts for approximately 3% of all congenital heart defects
(CHD) with an approximate prevalence of 1:10,000 live births (Lin et al., 2000),
most frequently diagnosed in the newborn mainly due to cyanotic congenital heart
disease (Sutherland and Ware, 2009). In individuals with heterotaxy any internal
organ that is asymmetrically positioned can be abnormal and the midline defect,
which results from disclosure of neural tube, occurs in approximately 40% of
patients (Zhu et al., 2006). The wide phenotypic spectrum seen in heterotaxy, in
combination with the lack of formal clinical guidelines for the evaluation, has made
the identification of patterns of laterality defects more complicated. Thus these
patients require an extensive diagnostic evaluation and multiple imaging studies in
order to define their anatomy as well as chromosome microarray analysis due to
associations with chromosome abnormalities.
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Table 1.1: Congenital anomalies associated with heterotaxy (Zhu et al., 2006)

Cardiovascular

Atrioventricular discordance
Atrial isomerism
Double outlet right ventricle
Pulmonary stenosis or atresia
Transposition of the great arteries
Single ventricle
Left ventricular outflow tract
obstruction
Septal defects
Total/partial anomalous venous
return
Interrupted inferior vena cava
Bilateral superior vena cava
Conduction system abnormalities

Gastrointestinal

Extrahepatic biliary atresia
Intestinal malrotation
Omphalocoele
Duodenal atresia/obstruction
Tracheoesophageal fistula
Annular pancreas
Microgastria
Midline liver
Right-sided stomach

Pulmonary

Hyparterial or eparterial bronchi
Impaired mucociliary clearance in
patients with ciliary defect

Central nervous system

Neural tube defect

Genitourinary/anal

Imperforate anus
Sacral dysplasia
Renal dysplasia
Horseshoe kidney
Fused adrenal glands
Bifid or septate uterus and vagina

Musculoskeletal

Vertebral and rib anomalie

Immune

Asplenia or polyspleni

Ear, Nose, and Throat

Cleft palate
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1.2-EPIDEMIOLOGY AND INHERITANCE OF HETEROTAXY AND OTHER DISORDERS OF LR ASYMMETRY
Situs inversus, referring to complete mirror image arrangement of all internal
organs, is estimated to occur in 1 in 8,000-25,000 individuals and is mainly due to
abnormal cilia function or absent of cilia lining the respiratory tract known as
primary ciliary dyskinesia (PCD). PCD is also associated with a wide variety of
human diseases such as bronchitis, infertility, hydrocephalus, anosmia, and retinitis
pigmentosa (Afzelius et al., 2001; Pan et al., 2005), and has an autosomal recessive
inheritance pattern.
Situs ambiguous, which refers to abnormal arrangement of internal organs
with discordance of thoracic and visceral anatomy is mainly characterized by
congenital anomalies and is estimated to take place in 1:10,000 live births (Lin et al.,
2000). Most cases of situs ambiguous occur sporadically and do not follow obvious
Mendelian inheritance patterns, although phenotypic characterization of families
suggests both autosomal recessive and dominant patterns with incomplete penetrance
due to evidence of familial clustering. Family studies have identified isolated cardiac
defects, isolated neural tube defects, or abnormal vasculature in unaffected
individuals (Morelli et al., 2001).
Laterality defects, which refer to any deviation from situs solitus including
the failure to generate asymmetry, can arise in a single individual (Kosaki and Casey,
1998; Winer-Muram, 1995) but are especially associated with monozygotic
twinning. Environmental factors such as exposure to drugs or chemicals such as

3

nitrous oxide, retinoic acid, phenylephrine, methoxamine, have been reported to
associate with L-R phenotypes in animal models (Levin, 2005).
Isolated dextrocardia, which refers to right-sided heart position, showed a
strong association with a family history of CHD and extracardiac anomalies. A
population based study of cardiovascular malformation indicated that maternal
diabetes and first trimester cocaine use are associated with heterotaxy (Kuehl and
Loffredo, 2002).
Heterotaxy most often occurs as a sporadic condition. Genetic mechanisms
underlying heterotaxy are still not completely known, but the familial studies have
suggested a complex inheritance or autosomal dominant and autosomal recessive
inheritance with reduced penetrance and variable expressivity. (Vitale et al., 2001;
Belmont et al., 2004; Zhu et al., 2006; Wessels et al., 2008).
X-linked inheritance is well documented in heterotaxy and is caused by
mutations in ZIC3 (Gebbia et al., 1997). A large number of genetic syndromes and
chromosome abnormalities have been associated with heterotaxy, including
aneuploidies, complex chromosomal rearrangements, and microdeletions (Bisgrove
et al., 2003; Ware and Belmont, 2008; Song et al., 2009). Reported examples are
patients with trisomy 13 or trisomy 18. In addition, a number of submicroscopic
chromosomal deletions, including 22q11.2 DiGeorge/Velocardiofacial Syndrome
(VCFS) syndrome, have been identified in patients with heterotaxy. Bisgrove et al.
(2003) reviewed unbalanced translocations, terminal deletions, inversions, and more
complex chromosomal rearrangements associated with heterotaxy.
4

Analysis of genes located within submicroscopic chromosomal imbalances in
patients with abnormal L–R asymmetry should be a useful tool in uncovering novel
genetic pathways in laterality defects. However, it is not yet clear what percentage of
isolated cardiac defects are mechanistically related to early L-R patterning
abnormalities. In addition, the true incidence of human L-R patterning defects is not
yet known and so further definition of the molecular basis may identify a higher
incidence that has been recorded and a better understanding of this genetic disorder.

1.3-L-R AXIS ESTABLISHMENT DURING EMBRYONIC DEVELOPMENT
The congenital disorder in patients with heterotaxy mainly results from
failure to establish normal L-R asymmetry during embryonic development, with
major morbidity and mortality resulting from complex cardiovascular malformations
(Sutherland and Ware, 2009). The L-R asymmetry of the heart is closely connected
to its function and alteration in cardiac situs represent a significant source of human
heart malformations (Kathiriya and Srivastava, 2000). Since the L-R axis is
established during early development, a basic understanding of an embryonic tissues
and molecular events involved in L–R axis formation is beneficial for initiating a
diagnostic work-up, understanding the genetic basis of disease, and assessing
recurrence risk.
The L-R axis is established early in embryogenesis subsequent to the
development of anterior-posterior (A-P) and dorsal-ventral (D-V) axes. Recent work

5

with model organisms has offered a detailed view of the steps taken to establish
asymmetry in the vertebrate (Bisgrove and Yost, 2001). In Fig.1.1, five steps in
developing L-R asymmetry in the mouse embryo are illustrated. The early stage of
L-R patterning occurs before cilia are established at the node, a transient embryonic
organizer. This involves processes such as planar cell polarity in which asymmetric
gradients are established within a cell, across a sheet of cells and ultimately
throughout the embryo (Aw and Levin, 2009). The signaling pathways and the
molecular mechanisms of early stage of L-R patterning during embryogenesis are not
yet well defined and may vary by model organism (Sutherland and Ware, 2009).

Figure 1.1: Overview of L-R asymmetry in mouse embryo (Sutherland and Ware, 2009). Evidence
shows intercellular asymmetry involving mechanism such as Planar cell polarity (PCP) take place
before the establishment of the node or cilia. During the second stage, the node and functioning motile
cilia form. Centrally located monocilia are motile and peripheral monocilia lack L–R dynein and are
immotile. In the next stage, the movement of cilia at the node creates a leftward flow of morphogens.
Nodal expression is initially bilateral, but becomes asymmetrically expressed on the left, providing
molecular evidence of L–R asymmetry. During the stage four, Nodal signal is propagated from the
node to the lateral plate mesoderm (LPM) where asymmetric gene expression is established. In stage
five, asymmetric signaling is propagated from the LPM to organ primordia in order for proper
morphogenesis to occur.

6

During the second stage of mouse embryo development, the node and
functioning motile and sensory cilia form. The genetic control of node
morphogenesis is unknown but it has been proven that Notch signaling, which allows
a cell-cell communication, is necessary for both proper node structure as well as later
asymmetric nodal expression (Krebs et al., 2003; Przemeck et al., 2003; Takeuchi et
al., 2007). In addition, at this stage the monocilia located at center are motile
compare to immotile peripheral monocilia (McGrath et al., 2003). This characteristic
allows the movement of cilia at the node, creating a leftward flow of morphogens,
which form the clockwise rotational motion of the cilia and creating a unidirectional
flow in stage 3, which is essential for proper L-R asymmetry (Sutherland and Ware,
2009).
In the next stage, as results of leftward flow of cilia, fibroblast growth factor
(FGF) signaling triggers the releases of particles carrying the morphogens Sonic
hedgehog and retinoic acid, which are pushed to the left of the node and trigger a
cascade of gene expression (Okada et al., 2005; Hirokawa et al., 2006). In addition,
the unidirectional flow of extracellular fluid bends the peripheral immotile cilia
surrounding the node, resulting in an asymmetric cytoplasmic calcium flux (McGrath
et al., 2003). These two pathways effect Nodal expression which initially is bilateral,
but becomes asymmetrically expressed on the left, providing the first molecular
evidence of L-R asymmetry which is critical for subsequent left-sided gene
expression in the lateral plate mesoderm (LPM) (Sutherland and Ware, 2009).
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In stage four, Nodal signal transduction pathway expressed in the left side of
the node and the signal is propagated to the LPM where asymmetric gene expression
is established. At the presence of an EGF-CFC cofactor, Nodal signals through type I
and type II receptors and activates two antagonists Lefty-1 (LEFTYA in human) and
Lefty-2 (LEFTYB in human) which are expressed in the midline and in the LPM,
respectively. This activation limits Nodal expression and subsequently inhibits the
transfer of left-sided gene expression across the midline of the embryo. Pitx2, a
homeobox transcription factor, is also activated by Nodal and is asymmetrically
expressed in the LPM as well as in various organs. This molecular asymmetry is
much conserved across vertebrates and the majority of the known human heterotaxy
mutations have been discovered in this pathway. However, mutations within this
pathway cause heterotaxy in a minority of cases, indicating that novel genetic
etiologies remain to be determined (Sutherland and Ware, 2009).
In the final stage, asymmetric signaling is propagated from the LPM to organ
primordia in order for proper morphogenesis to occur. The asymmetric Pitx2
expression persists after the disappearance of the Nodal signal, and involves in
organogenesis in the heart, gut, and lungs, demonstrating asymmetric expression in
developing organ primordia. Information about cardiac specific targets during
looping morphogenesis is currently lacking and needs further investigation.
Study of L-R asymmetry using model organism has shown that heterotaxy
may result from defects in any of these five steps. Isolated dextrocardia or CHD
related to abnormal laterality can also result from abnormalities at various stages of
8

L-R patterning. However, a detailed genetic mechanism of the pathway is still
remains to be determined.
1.4-CLINICAL AND PRENATAL EVALUATION OF HETEROTAXY
1.4.1-The clinical evaluation of heterotaxy
Although heterotaxy shows broad phenotypic variability, the approach to
studying this population is relatively straightforward. The first and most important
step during clinical evaluation of laterality defects is to identify the full phenotypic
spectrum of abnormalities in the proband and to determine whether it is a case of
situs inversus or situs ambiguous. This information is essential for patient
management as well as providing information that is critical for identification of the
possible underlying genetic etiology.
Patients with situs inversus should have evaluation of ciliary function. In
addition the signs of Bardet-Biedl syndrome (BBS), including obesity, retinitis
pigmentosa, and mental retardation, should be evaluated. Although situs inversus is
infrequently reported in BBS, it occurs at a significantly higher rate than in the
general population (Ansley et al., 2003). Mutations in BBS2 and BBS8 have been
reported in association with situs inversus. Five out of eight known BBS genes
encode basal body or cilia proteins, implying a potential for laterality defects
(Beales, 2005). Infantile nephronophthisis is another genetic disorder that is
associated with situs inversus. This is an autosomal recessive cystic kidney disease
which is caused by mutations in INVERSIN (Otto et al., 2003). Lacking evidence of
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cystic kidneys or stigmata of BBS, a patient with situs inversus is classified as having
PCD, previously known as immotile cilia syndrome, and therefore and should be
followed by a pulmonologist or allergist/immunologist as needed (Zhu et al., 2006).
Patients with situs ambiguous require an extensive diagnostic evaluation
directed toward defining the anatomy and preventing potential complications. The
evaluations tailored based on data collected from performing an echocardiogram
and/or cardiac MRI, abdominal and renal ultrasound, and vertebral X-rays. In
addition, the spleen should be evaluated by ultrasound and a peripheral blood smear
to detect the presence or absence of Howell-Jolly bodies, red blood cell inclusions
indicating abnormal spleen function.
A three-generation pedigree is an essential component of the evaluation. For
situs ambiguous, any family history of congenital anomaly is potentially
contributory. In addition, mouse models suggest that increased pregnancy loss may
be associated with mutations in genes responsible for L-R patterning (Zhu et al.,
2006). In addition, there are large numbers of other syndromes that are associated
with laterality defects that can be used for clinical evaluation (Aylsworth, 2001).
Among aneuploidies, both trisomy 13 and trisomy 18 can cause congenital anomalies
overlapping situs ambiguous that can potentially complicate prenatal counseling if
amniocentesis is not performed (Ware and Belmont, 2004). Microdeletion 22q11.2
can be detected by karyotype which is associated with laterality defects (Aylsworth,
2001). It is likely that a number of complex malformation syndromes result from
early developmental patterning defects in which laterality can be disrupted.
10

1.4.2-Prenatal evaluation
The frequency of identified heterotaxy cases on prenatal ultrasound has
increased as the result of advances in imaging technology (Berg et al., 2003). For
example, fetal echocardiography has provided a tool for detailed study of the
structure of an unborn baby’s heart. Early fetal heart block is commonly associated
with left isomerism and early detection of the disorder is critical for clinical
management (Jaeggi et al., 2005). In the absence of a syndromic diagnosis, the
prognosis of the fetus is largely based on the cardiac anatomy and/or the presence of
biliary atresia. Biliary atresia is a disorder of infants in which there is progressive
obliteration or discontinuity of the extrahepatic biliary system, resulting in
obstruction of bile flow, requiring liver transplantation within the first year of life
(Leyva-Vega et al., 2010). Biliary cystic malformations can be identified prenatally
and, although not specific for biliary atresia, are highly suspicious when identified in
conjunction with other laterality defects. Since the inheritance patterns of heterotaxy
is very complicated and varies among individuals, genetic counseling in prenatal
cases is complex. In addition to discussion of the anatomic defects and their
prognosis and management, counseling sessions should also include discussion of
both syndromic and nonsyndromic possibilities and an explanation of inheritance
patterns. However, to gain a better understanding of these disorders, analysis of
genes involve in L-R asymmetry would be a powerful tool in uncovering novel genes
and pathways in laterality defects.
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1.5-GENETIC RISK FACTORS AND MOLECULAR DIAGNOSTICS
Model organism studies have shown that functions of more than eighty genes
are required for normal asymmetric L-R organ development. While some of these
genes probably have a conserved function in humans and any mutation in them are
lethal, mutations in relatively few genes have been identified in patients with
heterotaxy. These include ZIC3, LEFTYA, CRYPTIC and ACVR2B, and single cases
of mutations in NKX2.5 and CRELD1 have been reported in patients with
dextrocardia (Watanabe et al., 2002; Robinson et al., 2003). The contribution of
mutations in these genes to heterotaxy or L-R patterning defects in the heart remains
to be characterized further in larger sample sets (Zhu et al., 2006). In all these
mutation studies, conventional methods of assessing the role of particular rare
variants as mutations have been used. This usually includes analysis of controls for
the particular variant. However, there is very little power to repeatedly detect rare
variants, even in very large control sets.

1.5.1-Zinc finger protein ZIC3
The zinc finger domains (ZFDs) of the Zinc family proteins have been
strongly conserved over the evolution of a broad range of eumetazoan animals
(Aruga et al., 2006) suggests they provide the structural basis for the essential roles
of Zic family protein in animal development (Aruga, 2004; Herman and El-Hodiri,
2002). In humans there are five members of the ZIC family that are involved in
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congenital anomalies (Grinberg and Millen, 2005). One of them, ZIC3, was the first
gene identified to have a casual role in defects in human laterality (Ferrero et al.,
1997; Gebbia et al., 1997). Mutations in ZIC3, which is on the X chromosome, can
cause the X-linked form of heterotaxy, HTX-1 (OMIM#306955).
ZIC3 was first identified as a gene preferentially expressed in mouse
cerebellum (Aruga et al., 1996) and has the ability to bind DNA and activate
transcription (Mizugishi et al., 2001). Zic3-deficient mice develop a broad range of
abnormalities in addition to heterotaxy such as neural tube defects, skeletal
patterning defects, cerebellar hypoplasia and abnormal behavior (Carrel et al., 2000;
Klootwijk et al.,2000; Purandare et al., 2002; Aruga et al., 2004).
ZIC3 protein is made of five tandemly repeated C2H2 zinc finger
transcription factors that are involved in early patterning of the vertebrate embryo. In
human, missense mutations that result in changes in cysteine 253 (C253S) or
histidine 286 (H286R) are found in heterotaxy patients and cause extracellular
localization of the mutant ZIC3 protein (Ware et al., 2004). Another mutation that
alters a tryptophan residue (W255G) is associated with transposition of the great
artery (TGA), a CHD that might be an expression of a L-R laterality disturbance
(Chhin et al., 2007). Loss of function of this gene has also been reported to associate
with other abnormalities such as double outlet right ventricle, and ventricular
inversion (Sutherland and Ware, 2009).
Approximately 1% of sporadic heterotaxy cases (male and female) are caused
by mutation in ZIC3. In addition, affected females have been described with point
13

mutations or with chromosomal translocations at this gene(Megarbane et al.,
2000;Ware et al., 2004; Fritz et al., 2005; Tzschach et al., 2006; Chhin et al.,2007).
Carrier females who are heterozygous for ZIC3 mutation are clinically unaffected
although a subset has situs inversus (Casey et al., 1993; Gebbia et al., 1997).
Deletion of the ZIC3 locus has been associated with situs ambiguous, suggesting the
cause of pathogenesis in the patients with the point mutations (Ferrero et al., 1997).
These findings have suggested that isolated CHD may be caused by genes
involved in L-R axis development and that there may be variable expression of
mutant alleles within and between families. It is currently unclear to what degree
ZIC3 mutations contribute to sporadic heterotaxy, and this information is necessary
to provide accurate counseling information to families. Mice models suggest that
ZIC3 acts upstream of Nodal signaling at the node, however its detailed
developmental function is not yet clear (Purandare et al., 2002; Ware et al., 2006).

1.5.2-NODAL, LEFTYA, CRYPTIC, and ACVR2B
NODAL is a member of the transcription growth faction (TGF)-β family and
is involved in cell differentiation. The pattern of NODAL expression and its
developmental function has largely conserved among vertebrates. In the mouse, it is
known to have an essential role in early embryonic development including mesoderm
and endoderm formation and L-R axis patterning. During gastrulation stage of
development, NODAL is expressed in the epiblast and visceral endoderm, and it
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induces its co-receptor Cripto, which controls A-P patterning. Lack of NODAL
expression in mice causes the absence of primitive streak and loss of mesoderm
formation (Conlon et al., 1994; Lowe et al., 1996; Zhou et al., 1993). The functions
of NODAL have been examined in other species, and in all of them NODAL
orthologs are expressed asymmetrically in the left side of the node as well as in left
lateral plate mesoderm (Schier and Shen, 2000; Whitman, 2001). This data shows
that the Nodal signaling cascade within the lateral plate mesoderm is required for LR patterning in vertebrates (Mercola and Levin, 2001; Hamada et al., 2002; Schier,
2003), and any disturbance in expression of NODAL can lead to polarity reversal of
visceral organs and heart looping (Harvery, 1998). Mutations in NODAL have been
identified in patients with heterotaxy following an autosomal dominant inheritance
pattern (Kosaki et al., 1999; Bamford et al., 2000; Goldmuntz et al., 2002; Selamet
Tierney et al., 2007; Roessler et al., 2008; Mohapatra et al., 2009).
Nodal signaling uses an Activin/TGF-β-like pathway mediated by several
Activin-like receptors (ALKs). NODAL signals via ALK4 and AKL7 in association
with either ActRIIA or ActRIIB (Whitman 2001). The activated receptor complex
phosphorylates an intracellular receptor-regulator known as Smads. This
phosphorylated complex binds to Smad4 and that results in its translocation to the
nucleus (Attisano and Wrana, 2002). This complex then can either bind DNA
directly or can interact with other DNA binding proteins such as transcription coactivator FoxH1 to regulate the promoters of various genes. In addition, FoxH1
regulates Nodal signaling pathway by binding to the NODAL and Lefty2 asymmetric
15

enhancer element (Saijoh et al., 2000). Mutations in several components of the Nodal
signaling pathway in animal models has exhibit defects in L-R axis development
(Pogoda et al., 2000; Yamamoto et al., 2001; Yan et al., 2002). Mutation in
components of the Nodal signaling pathway, such as genes encoding the ligand
(NODAL), ligand co-receptor (CFC-1), receptor (ACVRIIB), FOXH1, and midline
inhibitor (LEFTYA) within the Nodal signal transduction pathway, have been
identified in human heterotaxy (Kosaki et al., 1998; Bamford et al., 2000; Goldmuntz
et al., 2002; Selamet Tierney et al., 2007; Roessler et al., 2008; Mohapatra et al.,
2009). Biochemical studies indicate that Cripto (TDGF1) and Cryptic (CFC1) in
mouse and human form complexes with NODAL, ALK4/ALK7 and ActRIIB and act
as a co-receptor for NODAL at the cell surface (Bianco et al., 2002; Yan et al.,
2000).
Study on NODAL variants in 269 patients with heterotaxy or isolated
cardiovascular observed missense mutations in 14 unrelated patients (Mohapatra et
al., 2009). Functional analysis of the mutant proteins showed a decrease in Nodal
signaling. Similarly, functional analysis of mutations in Cryptic (CFC1), a gene
encoding an epidermal growth factor family protein, CFC1, which functions as a
NODAL co-receptor, revealed abnormal cellular localization of the mutant protein
(Bamford et al., 2000). ACVRIIB mutations were identified in 3 of 126 patients with
left–right anomalies and mutations in LEFTYA were discovered in 2 patients (Kosaki
et al.,1998). The study showed that each patient inherited the mutant allele from an
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unaffected carrier parent, indicating autosomal recessive inheritance pattern or
incomplete penetrance.

1.5.3-Other risk factors
With over hundred candidate genes identified through mouse models of L–R
patterning defects, it is likely that significant genetic heterogeneity will be found in
human heterotaxy. To date, the majority of genes identified have either not yet been
tested in larger heterotaxy populations or have been found to have mutations at a low
frequency (Watanabe et al., 2002; Robinson et al., 2003). For example, positional
cloning of a region involved in a reciprocal translocation in one patient identified
SESN1, a gene involved in L-R patterning. Functional analysis of this protein
revealed that it plays a role in activating Nodal signaling. However, the prevalence of
disease causing mutations in this gene is less than 1% based on an initial screen of a
heterotaxy cohort (Peeters et al., 2003, Peeters et al., 2006). Efforts are ongoing to
identify novel genes that cause or contribute to the heterotaxy phenotype. One of the
candidate genes that require a large population study in patients with heterotaxy is
CRELD1. Missense mutations in CRELD1 are associated with atrioventricular septal
defects (AVSD), including AVSD in patients with heterotaxy (Robinson et al.,
2003).
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1.6-CRELD1 AS A CANDIDATE GENE
CRELD1 is the member of a highly conserved family of proteins known as
CRELD (Cysteine Rich with EGF-Like Domains) (Rupp et al., 2002), that are
members of the TGF-superfamily, which contains a diverse array of multifunctional
cytokines. This group has one other homologous member, CRELD2. The two
members of this family are nearly identical except that CRELD1 is a cell surface
molecule, whereas CRELD2 is a secreted protein that is possibly a regulator of
CRELD1 function. These cell-surface/extracellular proteins are characterized by
tandemly repeated epidermal growth factor-like (EGF) domains and a unique motif
called the CRELD domain.
CRELD1 is located on chromosome 3p25 (Rupp et al., 2002) and is the first
recognized risk factor for isolated AVSD (Robinson et al., 2003), a common
congenital heart malformation affecting the atrioventricular valves and septa that
results in a mixing of oxygenated and non-oxygenated blood. In addition, CRELD1 is
becoming increasingly recognized as an important factor in cancer biology with
numerous proposed biochemical interactions.
CRELD1 missense mutations occur in almost 8% of individuals with AVSD
(Robinson et al., 2003), and 5% of Down syndrome-associated AVSD cases (Maslen
et al., 2006). The highly specific genetic association between CRELD1-missense
mutations and AVSD suggests that mutations in CRELD1 significantly increase the
risk of developing an AVSD. High level of incidence of AVSD has been reported in
heterotaxy patients, presumably due to physical disruption of septation from
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laterality defects. Missense mutations in CRELD1 suggest that defects in CRELD1
may increase the likelihood of AVSD in heterotaxy (Robinson et al., 2003).
However, a recent study on a CRELD1 knocked out (Creld1(-/-)) mice model
indicates that CRELD1 is not associated with laterality defects in mice embryos
(Redig et al., submitted).
Fig.1.2 compares Creld1(-/-) mice embryos with a Creld1(+/-) and wild type
Creld1(+/+) embryos. As can be seen, Creld1(-/-) embryos exhibited underdeveloped
organs such as telencephalons and heart. However, the positions of organs is the
same in Creld1(-/-) embryos relative to wild-type Creld1(+/+) with no sign of laterality
defects. This indicates that CRELD1 does not cause laterality defects (Redig et al.,
submitted), but it doesn’t rule out the possible role of CRELD1 as a risk factor for
developing AVSD in a heterotaxy population.
The basic biological function and definition of the CRELD1 biochemical
pathway is under investigation. Multiple alternate splice variants of CRELD1 suggest
that there are isoforms with diverse functions. CRELD1 can bind to RTN3, an
apoptosis-inducing protein responsive to endoplasmic reticulum stress, and controls
apoptosis activity of RTN3 (Xiang and Zhao, 2009). In addition, a recent study on
cell migration during development suggests the important role of CRELD1 in
polarized cell migration (Nystul et al., 2009), a process regulated by Notch signaling
which is necessary for proper node structure as well as asymmetrical nodal
expression.
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Figure 1.2: Mice embryos at the developmental stage (Redig et al., submitted). The two picture on far
left (A,A’) are showing the wild-type embryo, two in the middle (B, B’) are heterozygous for
Creld1(+/-) and the two other on the far right(C,C’) are showing the nocked out mice Creld1(-/-)
embryos. There is a broad abnormalities in Creld1(-/-) embryos especially in the head, which exhibited
underdeveloped telencephalons, T and underdeveloped olfactory placodes, OP. The position of Limb
buds (LB), olfactory placode (OP), branchial arch (BA), telencephalon (T), heart (H) are indicating
the absence of laterality defects in Creld1(-/-) embryos.

20

1.7-HYPOTHESIS
Despite all of the indications that CRELD1 plays a role in human early
development, no study has been done in large sample of patients with heterotaxy to
determine if mutations in CRELD1 are a risk factor increasing the likelihood of
AVSD in this population. To address this, we examined whether there is a significant
difference between the variables in this population. Our hypothesis and alternative
hypothesis are:
•

Hypothesis: there are missense mutations in CRELD1 which increase
the likelihood of AVSD or other CHD in heterotaxy patients.

•

Alternative Hypothesis: there is no novel mutation in CRELD1 effecting
susceptibility for CHD in this population.
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CHAPTER II: METHOD AND MATERIALS
2.1-CLINICAL EVALUATION AND SAMPLING
The study sample included 126 individuals with a diagnosis of heterotaxy
syndrome with or without heart defects, identified by the Baylor College of
Medicine, Houston, Texas and provided in collaboration with Dr. John Belmont. The
study population ranged broadly in age and sex.
A biological sample for genomic DNA isolation was obtained from each
individual, from blood or by buccal samples collected by mouthwash, by the
Belmont group using standard technology. The normal control population DNA
panels from Caucasian and Hispanic populations were obtained from the Coriell
Repository (Camden, NJ).

2.2-DESIGN OF OLIGONUCLEOTIDE PRIMERS
The coding and known regulatory regions of CRELD1 were screened for
point mutations by standard DNA sequencing of PCR amplified genomic DNA. PCR
amplification was done using previously designed primers and conditions (Robinson
et al., 2003). The primer sequences and amplification profiles are listed in table 2.1.
Primers were used to amplify ten exons and two promoter regions as well as at least
50 bp into introns from each junction in a total of seven amplicons.
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2.3-PCR AMPLIFICATION
For each patient genomic DNA sample, seven PCR reactions were performed
using the primers listed in table 2.1. PCR reactions for regions including exon 3,4,10,
and promoter region 2 were performed in a 25 µl reaction volume containing 100 ng
of genomic DNA, 25 pmol of each primer, and 12.5 µl of Invitrogen AccuPrime™
PCR SuperMixII.
For the rest of the exons and promoter region 1, PCR reactions were
performed in a 25 µl reaction volume containing 100 ng of genomic DNA, 25 pmol
of each primers, 5 µl of Herculase II buffer (5x), 2 µl of 10mm dNTPs, 1.25 µl of
DMSO, 0.25 µl of Herculase II Polymerase (Stratagene; La Jolla, CA, USA). PCR
cycling was carried out on a Veriti® Thermal Cycler (Applied biosystems, Ca, USA)
using a denaturation cycle at 95 ºC for 2 min, followed by 35 cycles of denaturation
at 95ºC for 15 sec and annealing (Table 2.1) 15 sec, and extension step at 72ºC for 30
sec and a final extension step at 72ºC for 7 min. The products were visualized by
standard ethidium bromide-agarose gel electrophoresis.

23

Table 2.1: Oligonucleotide primers for CRELD1 amplification by PCR.
Annealing
Temperature
(ºC)
62

Product
size
(bp)
685

Pro 2-F 5’ CGG TCG CTT CTT CCT TCT C
Pro 2-R 5’ AGA AGA CTG GGG AGG TGG AG 3’

63

665

CRELD1
Exons 1-2

E1-F 5’ AGC CTC TCC ACG CCC TCT A 3’
E2-R 5’ CCT AGC CCT ACA CCA GCA GAG 3’

62

600

CRELD1
Exons 3-4

E3-F 5’ GAG ACT TGA GGA GGG TGG TG 3’
E4-R 5’ AAG CCT TTC CCC ACT GAT TT 3’

58

800

CRELD1
Exons 5-6

E5-F 5’ TGT ATA GAT GAC CTC ACC TGG TTT 3’
E6-R 5’ CTG ACC ATC TTC CCA GAC CT 3’

58

400

CRELD1
Exons 7-8-9

E7-F 5’ CTC TGG CTT CAG CTT CCC TA 3’
E9-R 5’ GCC TGC CTT CTC TTT GAA TG 3’

63

800

CRELD1
Exon 10

E10-F 5’ CCA GGA ACA GGG ATA CGA GTG 3’
E10-R 5’ GGT GCT TAC CCC ACT CTC AAA 3’

58

400

Amplicon

Primer pair

CRELD1
Promoter
Region 1

Pro 1-F 5’ CTG CTT CGA CAG GCT 3’
Pro 1-R 5’ ATC CGG ATA TGA AGG 3’

CRELD1
Promoter
Region 2

2.4-PURIFICATION OF PCR PRODUCTS
Template quantity was adjusted based on the PCR product size (Table 2.2). 5
µl of PCR product was purified using 2 µl of ExoSAP-IT® (United States
Biochemical, Ohio, USA). The samples were incubated at 37°C for 15 min to
degrade remaining primers and nucleotides followed by incubating at 80°C for 15
min to inactivate ExoSAP-IT.
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Table 2.2. Template quantities for 1X cycle-sequencing run
Template

Template quantity

PCR product:
100-200 bp

1-3 ng

200-500 bp

3-10 ng

500-1000 bp

5-20 ng

2.5-SEQUENCE ANALYSIS
The templates were sequenced in both directions using the sequencing
primers, listed in Table 2.3, by the OHSU General Clinical Research Center DNA
Sequencing Facility. The sequencing electropherograms were compared with gene
sequences from GenBank accession number NM_001077415.1 using Mutation
SurveyorTM DNA Analysis software (SoftGenetics LLC, Inc).
Table 2.3: Oligonucleotide primers for CRELD1 exon sequencing
Region
Promoter Region 1

Primer pair
Pro 1-F-Seq 5’ CTG CTT CGA CAG GCT 3’
Pro 1-R-Seq 5’ ATC CGG ATA TGA AGG 3’

Promoter Region 1

Pro 2-F-Seq 5’ CGG TCG CTT CTT CCT TCT C
Pro 2-R-Seq 5’ AGA AGA CTG GGG AGG TGG AG 3’

CRELD1 Exons 1-2

E1-F-Seq 5’ CGC CCT CTA TCT GCA GGT CC 3’
E2-R-Seq 5’ GAG CAG AGA TTT GGC GGG GAG GGG A 3’

CRELD1 Exons 3-4

E3-F-Seq 5’ GGG TGG TGG GTG GGG TGG GGC 3’
E4-R-Seq 5’ CCC ATC TCC CCA GCC CTG TC 3’

CRELD1 Exons 5-6

E5-F-Seq 5’ CAC CTG CTT TGG TGT CTT CC 3’
E6-R-Seq 5’ TCC CAG ACC TAG CTA GGG CC 3’

CRELD1 Exons 7-8-9

E7-F-Seq 5’ TTC AGC TTC CCT ACT AAA TAG GG 3’
E9-R-Seq 5’ TCT TTG AAT GAG GAC CTC CC 3’

CRELD1 Exon 10

E10-F-Seq 5’ TAC GAG TGC CAG GCT GCA TC 3’
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2.6-ALLELE-SPECIFIC PCR (ASP)
The Single Nucleotide Polymorphism (SNP) database was queried to identify
DNA sequence alterations that were commonly accruing SNPs. In order to detect
SNPs for missense amino acid changes found at exon 5, amino acid position A206T,
first detected on sequencing data, allele-specific PCR analysis was used on the
patient sample and control population.
Genomic DNA was amplified by use of primers that match/mismatch one of
the alleles at the 3’-end of the reverse primer (5’-CATACCAGATGGCTGGTG-3’
and 5’- CATACCAGATGGCTGGCG-3’, mutant and wild type, respectively). The
reverse primers were coupled with upstream (forward) primer (5’CTGGTTTGGTGTCTTCCC -3’). Characterization of this assay demonstrated that
the wild-type exon 5 primer amplified genomic DNA from both the patient and
normal controls, whereas the mutant primer was capable of amplifying only genomic
DNA from the affected individual in whom the mutation had been characterized.
Table 2.4: ASP primer sequence.
Name

Primer sequence

PCR condition

CRELD1-A206T-200-F

CTG GTT TGG TGT CTT CCC

CRELD1-A206T-2nd-mut-R

CAT ACC AGA TGG CTG GTG

x 40

CRELD1-A206T-2nd-WT-R

CAT ACC AGA TGG CTG GCG

95 ºC x 2´
95 ºC x 15´´
62 ºC x 15´´
72 ºC x 15´´
72 ºC x 7´

CRELD1-T265A-2nd-mut-R

CTC ATA GGA GCC CTC AGC

CRELD1-T265A-2nd-WT-R

CTC ATA GGA GCC CTC AGT

x 40

CRELD1-T265A-200-F

GGT TGG CAA ATG TGG TCT C

95 ºC x 2´
95 ºC x 15´´
60 ºC x 15´´
72 ºC x 15´´
72 ºC x 7´
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The DNA samples were amplified by PCR using 100 ng of genomic DNA in
a 25 µl reaction containing 0.2 µl of 25 mM of each primer, 5 µl of Herculase II
buffer (5x), 2 µl of 10mm dNTPs, 1.25 µl of DMSO, 0.25 µl of Herculase II
Polymerase (Stratagene; La Jolla, CA, USA), and PCR cycling was carried out on a
Veriti® Thermal Cycler (Applied biosystems, Ca, USA). Condition for PCR were 2
min of initial activation step at 95 ºC followed by 40 cycles of denaturation at 95 ºC
for 15 sec and annealing at 62 ºC for 15 sec, and extension at 72 ºC for 30 sec and a
final extension step at 72 ºC for 7 min. The products were visualized by standard
ethidium bromide-agarose gel electrophoresis. In all cases the primers gave a single
band of the expected size, 200 bp.

2.7-POLYMORPHISM PHENOTYPING (POLYPHEN-2)
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2) was used to predict
possible impact of an amino acid substitution on the structure and function of
CRELD1. Polyphen-2 is a bioinformatics tool which uses multiple algorithms to
predict the impact of missense mutations on human protein structure. This tool
allows the analysis of all human non-synonymous SNPs publicly available via SNP
database.
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CHAPTER III: RESULTS

Out of 126 patients with heterotaxy, approximately 66% of them were also
diagnosed with different type of heart defects (Table 3.1). DNA sequence analysis of
CRELD1 in this cohort of 126 study subjects identified three different missense
variants (A206T, R329C and T265A) in three unrelated individuals, who had no
other mutations or rare variants identified in their genomes. A two base pair GA
deletion was found in non-coding sequence of ten other patients in intron position
9959990/1. Four previously characterized common polymorphic variants (rs279552,
rs57022843, rs9853613, rs2302786) were also observed in this population but not
investigated further. In addition, three other synonymous variants (L304L, P315P
and Q368Q) previously seen by our laboratory in other studies were detected (Table
3.2), but were not further characterized as they appeared to have no functional
significance.
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Table 3.1: The frequency of different abnormalities found in heterotaxy population of
study. Other heart defects were including right sided cardiac apex, mesocardia,
hypoplastic left heart syndrome, Left Atrial isomerism, double aortic Arch, L-loop
Patent ductus arteriosus, double outlet right ventricle, hypoplastic left ventricle , and
interrupted inferior vena cava
Abnormality

Number of patients

ASD,VSD,AVSD with or without other heart defects

8

D/L-loop TGA

40

D/L-loop TGA with CoA

8

D/L-loop TGA and other heart defects

9

Situs inversus with or without dextrocardia

4

Dextrocardia with other heart defects

7

Heterotaxy only

38

MGA and other heart defects

4

Other types of heart defects

8

Key: ASD, atrial septal defects; VSD, ventral septal defects; AVSD, Atrioventricular Septal Defect;
TGA, transposition of great arteris; CoA, coarctation of the aorta; MGA, malposition of great arteries

3.1-PATIENT1-A206T MUTATION
Patient 1 was diagnosed with AVSD and dextro-Transposition of the Great
Arteries (d-TGA), referred as a complete transposition of the great arteries (Fig.3.4,
B). Analysis of the subject’s DNA revealed a heterozygous missense mutation. The
single-base G

A substitution, at exon position G9957689GA, and cDNA position

615 (c.615G>A), is located in exon 5 and results in a substitution of threonine for
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alanine at amino acid position A206T (Fig.3.2). The amino acid is located in the
CRELD domain of CRELD1 (Fig.3.3) with extracellular function. The mutation
changes the amino acid located at the sequon position of one of the two N-linked
glycosylation sites of CRELD1. Glycosylation is a common post-translational
modification for protein molecules involved in cell membrane formation. N-linked
glycosylation requires the consensus sequence Asn-X-Ser/Thr which X can be any
amino acid but proline. The N-linked glycosylation begins with the addition of a 14sugar precursor to an asparagine amino acid located at the sequon, and it allows the
protein to fold correctly followed by further modification in the endoplasmic
reticulum (ER) and Golgi. The first N-linked glycosylation site in CRELD1 is
located at amino acid position 79 and the second one is at 205 (Fig.3.1). The
mutation at this region is possibly affecting the efficiency of glycosylation.
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410
420
TGYWLSERSD RVLEGFIKGR

Figure 3.1: CRELD1 protein and the relative position of amino acids. Two N-linked glycosylation
sites are shown with the box. The amino acid change is labeled with red color.
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As seen in Fig.3.2 B, the region is conserved within human and bovine but
different in mouse. Based on PolyPhen2 analysis this mutation is suggested to have a
benign effect on CRELD1 protein structure. The affected subject is of Hispanic
descent. The base substitution was not detected in 93 chromosomes from a Hispanic
control population indicating that there is <5% chance the mutation is a
polymorphism in that population with 95% confidence (Collins and Schwartz 2002)
suggesting the variation is unlikely to be a polymorphism.
A

B

A
5’CGCAACGCCAGCCAT3’
R N A S
H
T

Human QAGYGGEACGQCGLGYFEAERNASHLVCSACFGPCARCSGPEES
Bovine QAGYGGEACGQCGLGYFEAERNASHLVCSACFGPCARCSGPEES
Mouse QAGYGGEACGQCGLGYFEAERNSSHLVCSACFGPCARCTGPEES
Figure 3.2: A. Sequence analysis identifying missense mutations in CRELD1. The arrow on the
electropherogram indicates the variant nucleotide, with the wild-type sequence shown below. The
altered nucleotide is shown in green. The single-letter amino acid translation is under the first base of
each codon. The altered residue is in red. Sequences from the complementary stand showed the same
heterozygous change. B. Alignment part of the sequence of CRELD domain of human with bovine
and mouse.
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A206T A265T

R329C

A

CRELD domain
EGF domains

B
cb-EGF domains

Extracellular Space

Type III transmembrane domains
Carboxyl-terminal domain

Cytoplasm
Figure 3.3: A. Diagrammatic representation of CRELD1 protein (Robinson et al., 2003). The relative
position of three amino acid changes found in heterotaxy patients are indicated by the arrows above
the diagram of CRELD1. B. A diagrammatic representation of CRELD1 showing the predicted
domain structure and cell membrane topology (Rupp et al., 2002).

3.2-PATIENT2-T265A MUTATION
The second alteration was found in a South Asian Indian patient with TGA,
coarctation of aorta (CoA), AVSD, and double inlet left ventricle (DILV). The single
base substitution of A to G at cDNA position 792 (c. A792G), was identified at exon
7 of DNA patient. This results in a substitution of alanine for threonine at amino acid
position 265, located in the highly conserved region of the CRELD domain (Fig.3.5,
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A and B). The base substitution was not detected in 102 race-relevant control
chromosomes (personal communication, Dr. Subrata K. Dey, West Bengal
University of Technology, India). This data indicate that there is less than 5% chance
that the mutation is a polymorphism in that population with 95% confidence (Collins
and Schwartz, 2002) suggesting the variation is unlikely to be a polymorphism.
Polyphen-2 analysis of mutation indicates that the mutation has a structural
damaging effect on CRELD1 protein.

A

D

B

C

www.texasheartinstitute.org

Figure 3.4: Illustration of different heart defects. A. is showing AVSD also known as canal defect
which is a defect involves holes between the two ventricles and atriums. B is showing the TGA where
the positions of aorta and pulmonary artery have been reversed. The coarctation of aorta is illustrated
in C. D is comparing the normal heart (on the left) with DILV (on the right) where the position of
great vessels and ventricles are reversed and both atriums are connected to the left ventricle.
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A

B

A
5’GCGTGAACGCTGAGG3’
V N T
E G
A

HumanLKCVDIDECGTEGANCGADQFCVNTEGSYECRDCAKACLGCMGAGP
BovineLKCVDIDECGTERASCGADQFCVNTEGSYECRDCAKACLGCMGAGP
MouseLKCVDIDECGTEQATCGADQFCVNTEGSYECRDCAKACLGCMGAGP
Figure 3.5: A. Sequence analysis data, identifying the second missense mutation in CRELD1. The
arrow on the electropherogram indicates the variant nucleotide, with the wild-type sequence shown
below. The altered nucleotide is shown in green. The single-letter amino acid translation is under the
first base of each codon. The altered residue is in red. Sequences from the complementary stand
showed the same heterozygous change. B. Alignment of the sequence for the topological domain from
human, bovine, and mouse CRELD1 gene.
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3.3-PATIENT3-R329C MUTATION
The third alteration was found in a Hispanic patient with a situs inversus,
AVSD, and asplenia, a congenital absence of the spleen which is usually
accompanied by complex cardiac malformations, malposition and maldevelopment
of the abdominal organs, and abnormal location of the lungs (OMIM# 208530). The
patient had a family history of two female siblings who died in utero. The first
sibling was diagnosed with pulmonary artery absence (PA hypoplasia), dysplastic
tricuspid valve, hypoplastic thymus, asplenia; the second sibling died from cystic
hygroma, and liver calcification. No samples were available from the siblings for
farther study.
The mutation found in this patient results in a substitution of cysteine for
arginine at amino acid 329 (R329C) in exon 9 which is located in a highly conserved
region among species (Fig.3.6, A and B). This amino acid is located in the second
calcium-binding EGF (cb-EGF) region, leading to change in β-sheet folding in the
secondary structure of CRELD1 (Robinson et al., 2003). This is a recurrent mutation
that has been identified in individuals with non-syndromic AVSD (Robinson et al),
and AVSD with Down’s syndrome (Maslen et al, 2004). The mutation was not
detected as a polymorphism in previous studies (Robinson et al., 2003; Kusuma et
al., 2011), and has been shown to change the protein conformation (Robinson et al.,
2003).
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A

B

C
5’GCGGTTATCGCTGCA3’
I
G Y R C
C

Human VDECETEVCPGENKQCENTEGGYRCICAEGYKQMEGICVKEQIPESA
Bovine VDECETAVCQGENQQCENTEGSYRCICADGYKQMEGICVKEQIPESA
Mouse VDECETVVCPGENEKCENTEGGYRCVCAEGYRQEDGICVKEQVPESA

Figure3.6: A. Sequence analysis data, identifying the third missense mutation in CRELD1. The arrow
on the electropherogram indicates the variant nucleotide, with the wild-type sequence shown below.
The altered nucleotide is shown in green. The single-letter amino acid translation is under the first
base of each codon. The altered residue is in red. Sequences from the complementary stands showed
the same heterozygous changes. B. Alignment part of the sequence for the topological domain from
human, bovine, and mouse CRELD1 gene.

3.4-OTHER SIGNIFICANT VARIANTS IN CRELD1
Table 3.2 summarizes the other non-synonymous and synonymous variants
found in this heterotaxy population. A non-synonymous variant A to G substituting
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valine to methionine at amino acid position M13V is located in exon1. All patients’
DNA samples in this study carried this SNP variant. This SNP was found in data
base SNP, indicating there is a polymorphism for this variant and suggesting its
benign effect on protein structure. PolyPhen-2 analysis also suggested that the
mutation is unlikely to change the protein structure or function.
A two base pair GA deletion was found in chromosomes of ten patients,
located at a non-coding sequence of CRELD1. The deletion is 52 base pairs upstream
of the branch point located in intron eight and probably does not have a significant
effect during splicing process. In addition, homozygous substitution of A for G at
intron position G9957920A, located at intron 6, was detected in all of the patients’
DNA samples. This SNP is located thirty base pair downstream of intron/exon
boundaries, indicating that it is unlikely to affect splicing. No data was found in
database for this SNP. Four other known SNPs (rs279552, rs57022843, rs9853613,
rs2302786) were also identified for which no significant effect has been reported for
them. In addition, three other rare synonymous variants L304L, P315P, and Q368Q
were detected. It was observed that all three amino acids coded for CRELD1 are
highly conserved among human, mouse, and bovine.
The first synonymous variant was detected as a heterozygous C to T silent
mutation at L304L located at the end of the exon 8. Another heterozygous silent
mutation was detected in three unrelated individuals. The variant was a substitution
of A for G at amino acid position P315P. This amino acid is located at the second cbEGF domain of CRELD1. The last heterozygous silent mutation was found in a
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patient, changing the base pair G to A at amino acid position Q368Q which is within
the transmembrane domain of CRELD1. These synonymous variants were not
further characterized, although it should be noted that synonymous SNPs can affect
splicing via the regulation of splice enhancers or inhibitors (Parmley et al., 2006;
Nielsen et al., 2007).

Table 3.2: Synonymous and non-synonymous variants in CRELD1 found in the heterotaxy population
Variants

Location

Functional group

G>GT (heterozygous)

Promoter 2 at 9951009

9

G>T (homozygous)

Promoter 2 at 9951009

1

T>TC (heterozygous)

Promoter 2 at 9950860

3

C>CT (heterozygous)

Promoter 2 at 9950628

1

A>G (homozygous)

Exon 1, M13V

All samples (126)

A>AG & A>G

Intron 3 at 9954660

23% heterozygous
11% homozygous

G>A (homozygous)

Intron 6 at 9957920

All samples (126)

C>CT (heterozygous)

Exon 8, L304L

GA deletion

Intron 8 at 9959990/1

G>GA

Exon 9, P315P

C>CT (heterozygous)

Intron 9 at 9960229

G>GA (heterozygous)

Exon 10 at Q368Q

CRELD domain

Number of patients

1
10

cb-EGF domain

3
1

Transmembrane

1
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CHAPTER IV: DISCUSSION

This study demonstrates that there are missense mutations in CRELD1 that
may act to increase
ncrease the likelihood of AVSD or other CHD in heterotaxy patients. In
this study three different heterozygous missense mutations in CRELD1 were
identified in three unrelated individuals from a patient population of 126 who were
diagnosed
gnosed with heterotaxy. Approximately 66% of the heterotaxy pop
population
ulation had
different types of heart defect
defects (Fig.4.1, A). The three individuals carrying mutation
in CRELD1 were diagnosed with different forms of heart defects in addition to
AVSD which accounts
nts for about 9% of patients with heterota
heterotaxy
xy and heart defects
(Fig.4.1, B) and approximately 6.3% in total heterotaxy population used in this study.
All three mutations were identified in highly conserved regions of CRELD1 and can
alter
ter CRELD1 properties. They are suggesting that mutation in CRELD1 may
increase the susceptibility of CHD in the heterotaxy population.
B

A

66.7%

33.3%

Figure 4.1: A, Approximate ratio of heterotaxy patients diagnosed with heart defects and without
heart defects in study population. B, The ratio of different types of heart defects in heterotaxy patients
with heart defects found in this population
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In one case the mutation was an A to T transition in exon 5 at cDNA position
615 (c.615A>G) that results in a substitution of threonine for alanine at amino acid
206 (p.A206T) in the CRELD domain of CRELD1. This domain has extracellular
function and is 333 amino acids long (p. 30-362) and contains two potential N-linked
glycosylation sites one at amino acid position 79 and 205. N-linked glycosylation of
some membrane proteins is critical for proper folding, co-assembly and subsequent
trafficking through the biosynthetic pathway, suggesting that it is necessary for
proper functional role of CRELD1. The mutation changes the amino acid located at
sequon position of the second N-linked glycosylation site. The sequon position is
Asn-X-Ser or Asn-X-Thr, where X is any amino acid except proline. In CRELD1 the
sequon position is Asn-Ala-Ser. The mutation, A206T, changes the alanine to
threonine. According to the consensus sequence X can be any amino acid except
proline, but changes in the sequence of this sequon have shown to have a major
effect on the ability of various tissues to utilize N-linked glycosylation signals
(Nishikawa and Mizun, 2001).
Therefore this alteration would not likely abolish glycosylation, but it could
affect the efficiency. Using the bioinformatics tool, PolyPhen-2, suggests that this
variant is unlikely to affect the protein structure. However as can be seen in Fig.4.2,
the molecular formula for alanine is C3H7NO2. This amino acid is non-polar and
hydrophobic and is known to be ambivalent, meaning it can be inside or outside of
the protein molecule. On the other hand, threonine is slightly polar with a molecular
formula of C4H9NO3, and compared to alanine it has one extra carbon and hydroxyl
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group making it a hydrophilic molecule. Although Polyphen
Polyphen-2 indicates that this
substitution will have a benign effect on protein structure, my analysis suggests that
this mutation may have the potential to significantly change the protein structure.
A

B

Figure 4.2: Alanine
nine (A) and threonine (B) chemical structure.

In addition, this non
non-synonymous
synonymous variant is located in the CRELD domain
that has extracellular function and such non-conservative alteration in CRELD1 can
affect its proper function. This alteration was not present in 93 race-rele
relevant control
chromosomes, indicating the novelty of this mutation and suggesting an association
of risk of developing AVSD that may work in concert with addition factors such as
heterotaxy in this study. Further study can be used to confirm our expectation on
changes in protein structure by analyzing a recombinantly expressed mutant
CRELD1 in which the physical properties of mutant protein can be compared with
wild-type CRELD1.
The second mutation was a single base alteration of A to G at cDNA position
792 (c. A792G) causing amino acid substitution of alanine for threonine at amino
acid position 265 (p. T265A). This SNP is within the exon 7 and located in a highly
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conserved region CRELD domain with extracellular function. Fig.4.2 shows the
chemical structure of these two amino acids. This amino acid change will reduce the
polarity of the protein and subsequently can alter its function.
Based on the analysis using PolyPhen-2, this region is highly conserved
among more than 20 different species and mutation at c.256 is predicted to have
damaging effect on the protein structure. Although the specific effect of this mutation
on the structure of CRELD1 is still unknown. The patient with this mutation exhibits
a broad range of heart defects in heart valves and chambers in addition to TGA,
AVSD, and coarctation of aorta (CoA). Race relevant population study confirmed the
novelty of this mutation. This data is consistent with my hypothesis that there are
mutations in CRELD1 that can increase the risk of developing CHD in heterotaxy
population.
The last mutation was found in a patient with situs inversus with AVSD and
asplenia. The mutation is a C to T transition in exon 9 at cDNA position 985 (c.985
C>T) that results in a substitution of cysteine for arginine at amino acid 329
(p.R329C). The chemical structure of these two amino acids is shown in Fig.4.3. The
mutation is in a very highly conserved region in the second cb-EGF domain of the
protein. This mutation was previously detected in individuals with non-syndromic
AVSD (Robinson et al., 2003) and AVSD with Down’s syndrome (Maslen et al.,
2006; Kusuma et al., 2011) and was determined to not be present in race-relevant
control chromosomes indicating that it is a disease-specific mutation.
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CRELD1 has two highly conserved cb-EGF domains (Fig. 3.3, B).
B The first
cb-EGF
EGF domain is 41 amino acids long, at amino acid position 153 to 193. The
second cb-EGF
EGF domain consists of 40 amino acids (p.305
(p.305-344).
344). These domains have
a very specific disulfide bonding pattern which iiss essential for proper protein
function (Robinson et al., 2003). Consequently, addition of a free cysteine residue, as
occurs with this mutation, change the β-sheet
sheet in the secondary structure of CRELD1
and would be expected to interfe
interfere with protein folding (Fig.4.4).
B

A

Figure 4.3: Arginine (A) and cysteine (B) chemical structure.

Accordingly, previous studies have shown that the p.R329C mutation alters
the protein structure (Robinson et al., 2003). Furthermore, this amino acid position is
conserved as an arginine
ne residue among mammals (Fig.
(Fig.3.6, B).
). Taken together, these
data suggest that the mutation p.R329C is involved in causing CHD in heterotaxy
patients.

In this study 84 out of 126 (67%) patients with heterotaxy had a broad range
of heart defects. Based on this study, CRELD1 mutations had a prevalence of about
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2.4% in total heterotaxy population. Identification of CRELD1 mutations in 3 out of
84 heterotaxy patients diagnosed with broad range of CHD suggesting the prevalence
of CRELD1 mutations appears to be approximately 3.5% in heterotaxy population
with different types of heart defects. In addition, all three mutations were found in
patients with heterotaxy who were also diagnosed with AVSD (3/8) suggesting a
high prevalence of 37.5% in this portion of the population. These data suggest that
defects in CRELD1 may contribute to the pathogenesis of AVSD and CHD in the
context of heterotaxy. This is consistent with previous studies that demonstrated that
CRELD1 mutations were associated with AVSD and heterotaxy as well as
nonsyndromic AVSD (Robinson et al., 2003; Maslen, 2004). However, the high
incidence of CRELD1 mutations in individuals with heterotaxy and AVSD indicates
that the heterotaxy background significantly sensitizes those individuals towards
developing an AVSD since the incidence of CRELD1mut-associated AVSD in other
populations.
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Figure 4.4: Diagrammatic representation of the two cb-EGF domain of CRELD1. The R329C
mutation is indicated by the arrow. Conserved amino acidresidues defining cb-EGF domains are
indicated by the single letter amino acid code. Black lines show the disulfide-bonding pattern for the
conserved cysteine residues (Robinson et al., 2003).

Consequently, based on these results, I conclude that CRELD1 mutations in
general may increase the risk for developing an AVSD and CHD in heterotaxy
patients. However, it is very important to consider that in the process of L-R
asymmetry and heart development, both are following a very complicated pathway
and many factors can affect their process. The question remains as to what
combination(s) of factors is required to exceed the threshold causing a complete
AVSD and CHD. The results of this study support the premise that mutations in
CRELD1 are a risk factor for AVSD and CHD in heterotaxy population.
Previous studies suggest that combinations of rare mutations, as see in this
study, in genes that control early embryonic L-R patterning and environmental
factors during embryogenesis are causing most of the cases heterotaxy with heart
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defects. Future works will have to focus on studying the other candidate genes such
as NKX2.5 in a larger population (Belmont 2004). Such information will provide the
factors effecting disease susceptibility in heterotaxy population. These can lead to the
ability of early disease detection and relatively in future to therapeutic ways of
restoring the function of altered genes.

FUTURE STUDIES

Mouse model can be used to study on how mutations in CRELD1 would
increase the risk of developing AVSD and CHD in heterotaxy population. This can
be done using F1 generation by crossing heterotaxy mouse Zic3(+/-) and Creld1(+/-)
mouse and studying the rate of heart defects in their progenies. In addition, more
study has to focus on looking for other unknown genes that increase the
susceptibility of developing AVSD and CHD in heterotaxy.
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Appendix: CRELD1 genomic sequence.
acgt = R pcr primer
acgt = R seq primer

acgt= F pcr primer
acgt= F seq primer
CRELD1 Genomic

Pro1R

9949321

ctggcctgcc tactctttgc cgctgcgctt tccctcatcc tccttctcaa aaaggatcac

9949261

gtttctaact cttcttctct gggtctccca gacatccaca agcgctgggc cctcgtgtgg

9949381

gcgaaaggtg agcgcttccc ggctccccat tcccctgggg gaggaccaga gtggctgtgg

9949441

gagttctccg agggaaagcg gcggccgagc tcactggctg cctccgcccc tctcccctaa

9949501

cagggtggct gaggctcttg aaacaggacg tccgctcggg gggtgagtgg gagcaagcgc

9949561

tgggcggagg gccgcccccg gggagccagg cctgtgccag ctcacctctt ccctccccat

9949621

ctgttttctc cggcagcggc cgccaggggc cgcgcggctc tgctcctcta ctcagccgat

9949681

gactcgggtt tcgagcgcct ggtgggcgcc ctggcgtcgg ccctgtgcca gctgccgctg

9949741

cgcgtggccg tagacctgtg gagccgtcgt gaactgagcg cgcaggggcc cgtggcttgg

9949801

tttcacgcgc agcggcgcca gaccctgcag gagggcggcg tggtggtctt gctcttctct

9949861

cccggtgcgg tggcgctgtg cagcgagtgg ctacaggatg gggtgtccgg gcccggggcg

9949921

cacggcccgc acgacgcctt ccgcgcctcg ctcagctgcg tgctgcccga cttcttgcag

9949981

ggccgggcgc ccggcagcta cgtgggggcc tgcttcgaca ggctgctcca cccggacgcc

9950041

gtacccgccc ttttccgcac cgtgcccgtc ttcacactgc cctcccaact gccagacttc

9950101

ctgggggccc tgcagcagcc tcgcgccccg cgttccgggc ggctccaaga gagagcggag

9950161

caagtgtccc gggcccttca gccagccctg gatagctact tccatccccc ggggactccc

9950221

gcgccgggac gcggggtggg accaggcgcg ggacctgggg cgggggacgg gacttaaata

9950281

aaggcagacg ctgtttttct acccatgtgg cccacacgcg tctccgtttc agtggcgggg

9950341

ctggcaaacg tcattcccta gccccgcggc cctttaaagc ccggacaggt gcagctcggt

9950401

gccgcctctg gttggctggc gtggggtgac gtaatggcac atggcccgtc gccattggct

E1Rseq

Pro 1

9950461

gggcggcaag ctccgccccc tggactgcgg cgcgggtggg ggttgTGCGT TTTACGCAGG

9950521

CTGTGGCAGC GACGCGGTGA GGAGACGGCC CACGGCGCCC GCGGGCTGGG GCGGTCGCTT

Pro2F

9950581

CTTCCTTCTC CGTGGCCTAC GAGGgtctgg atccttctct gccggctcgt gggccgtgcc

Pro2Fseq

9950641

tttgcccttc tgcgaggccc tgaatctgat cccttccctt catatccgga tccgggctcc

9950701

tccctccaag cccggggttc cggacacctc ccccaagaca acccctctgg cctcctctcc

9950761

ttcagtactt ggaatctgat ctcttctccc taattctgcg gatccggccc ctaatattct

Pro1Rseq

Pro2Rseq
Pro2R

Pro1F
Pro1Fseq

9950821

ttatcagacc ctcagacaag aggctgactt ctgccccctt gtcaaggagc gaggccactt

9950881

tcctctccac cccatgctag cgaggataac ttatttctct tctggaattg catcttatgc

9950941

gcctttcccc acccatcccc acagcccctg caatacccag tttggcctct tttgcttgta

9951001

ataacgcaga tcccagcgcc acggcacctt agaacagacc tttttctttc tcgcgtgggg

9951061

cctgactcct tcagtgaagc ctctccacgc cctctatctg cagGTCCCCA GCCTGGGTAA

9951121

AGATGGCCCC ATGGCCCCCG AAGGGCCTAG TCCCAGCTAT GCTCTGGGGC CTCAGCCTCT

9951181

TCCTCAACCT CCCAGGACCT ATCTGGCTCC AGCCCTCTCC ACCTCCCCAG TCTTCTCCCC

9951241

CGCCTCAGCC CCATCCGTGT CATACCTGCC GGGGACTGGT TGACAGCTTT AACAAGgtgg

9951301

gtgcaccggc agcctcgtta gaggggaaca cagcgattta gagtggggaa ctctgggatg

9951361

caaatctgcg tggatttaag tttcatcttg gtctcttact agttgtatgg ccctaggcag

9951421

gttgcctttc tgtgcctcag tttcctagtc agtagaacag tgaagtgcta gcatgtgcca

Pro 2

E1-2F
E1Fseq

Exon 1

E2Fseq

57

9951481

ggcactgtac ttagctatta ctaattttct gtttccagGG CCTGGAGAGA ACCATCCGGG

9951541

ACAACTTTGG AGGTGGAAAC ACTGCCTGGG AGGAAGAGAA TTTGTCCAAA TACAAAGACA

Exon 2

E2Rseq

9951601

Ggtaaggggc tgctggggga aggggtgtat attcccctcc ccgccaaatc tctgctctgc

E1-2R

9951661

tggtgtaggg ctaggaactc ttggggagca cttattcatt caacaaatag cactgaacat

9951721

ctatagtata gcagtaaaca aggcaagcaa aatgccccct tcctggagct cacattctag

9951781

tagagaagac aagcagtgaa tgagtaagtg aataatatta tgtcagatga agaacaaaca

9951841

gtgaagcacg gtagactgca ggacggtggg aggcaaggtg ttcaaggttt ggcatttgaa

9951901

cagagagaca ggaagtgaag aagcgagcta tgtgacaggg agggaattgg gcagaggatg

9951961

ggactgagct tggtgtattt gagaagtggc tggagtggag tgagccaagg ggagagtgct

9952021

agaaggtgaa ggcaaaggct taagcctcga gggctacaga aaagagttta gatttttttt

9952081

ggagtgtaat gggaagctct tggaaggcta tgagcagaaa aagtgatact gtcttctcta

9952141

cacctttaaa gattactcac actgctatgt agcaaacgga ttgtaagggg caagggcgga

9952201

ggaagcaggg agaccagttt gggaggcaag tgcatcatct aggtacaaag gcaacacaag

9952261

ctagtgtggt atctagtgga ggacatgatg aagaggtcac agtctgggta tattttgcag

9952321

agagaacaat aggacctggt gatagattca ttatgggtat agagaaacag tagaataaaa

9952381

gatgcttact agattttggg cctgagcaac tgggtgagta gtgcagctgt tttctaagat

9952441

ggtgagatgc gaaaccgaga aggtttaggg gaggggtggg atgtggtgtt ctttgaacgt

9952501

attgggctga aatgtccatt agacatccag gtagactcca tacaaatctg gaattcagaa

9952561

aagagtagga attggaaaca ggaatttgag agttgtcatt atatagtcag tatgtaaaga

9952621

aagccatggg aaggatacag aaagccatta tatagtcaat atatgtaata cagaaagcca

9952681

tttatatagt cagtatgtaa agaaaggcat gggaaggata cagaaaggcg agccctgagc

9952741

cctccagctt ttcaaagtca gatggaagag gagtcagcaa aggctcagag ttagacctgg

9952801

ttgtcggttc ttaacctctc agagccacag tttcttcacc tgtaaaatgg ggatattaat

9952861

acctggtttg cctatttcat agaagtgtgg aaaaggctta actgggatgc ccactagaaa

9952921

taaaggtttt gttattatgt aacattggtc attttctctt ttccttcgcc gggcctgagt

9952981

ttcctcattc aggaatgagg ggattggcta agacaacccc agaggcactt ccagctttgt

9953041

aatggctcct gcgttgcttg cttttttaaa tcacctccta tatgccaggc actgtgccag

9953101

accctttaaa tacaggatat aagacatcaa atatttatat atgtgtgtat atatatgtgt

9953161

gtgtgtatat atatatgtgt gtgtatatat atgtgcatat atgtctgcgt atatatatgt

9953221

gcgtatatat atgcgtatat atatatatat atgtatatat ttgtggtaaa atacacataa

9953281

aaaatttccc attaaagaca tttaataata tttacaatgt tgtgtaacca tcaccactat

9953341

gtagttccag aacattttca ttaccccccc aaaaaatcct atacctatta cacagccact

9953401

ccctattctc cccttccctc ggctcttggc aatcactaat ttgtgttagt caagcagaaa

9953461

ttatggattt gctgatttca ttggaatcat aaaatatgtg gccttttgtg tctggctagt

9953521

ttcacttagc ataatgtttt caaggttcac ccataccgta gcatatatca atacttattc

9953581

ctttttatgg ctgaataata ttctcatttg gctgtaccac attttgttta accatgcatc

9953641

agttgatgga catctgcatt gtttctacct tttggctgtt gtgaatagtg ctgctatgaa

9953701

cattgtctac aagttttcgt ttgaacacct gttttccatt cttttgggtc tatatccagt

9953761

agtggaattg gcaggtccta tggcaattcc atgttttact tattgaggaa ctgcttttcc

9953821

acagtggtga tgccattttg tattcccacc tgcagtgtgg gaggattcta atttctccac

9953881

atccctgcca acacttgtta taggatgtat ttttagccat atctacccag caagggtatt

9953941

atattccatt gctcagatgc aggaactgat gtatgttaca acaaacctgc agggaaggta

9954001

ttgtcatccc cattttacag atgacaaaac aaagaggttc agagaggtta agtgacttgc

9954061

ccactagatc taccactaga tttgaaccca ggtctctctg cttcccagaa ccatgacccc

9954121

ttccattata cctcatggcc tctcctttga tattttcacc gcacgaggaa gggtggagag

E3F
E3Fseq

58

9954181

agacttgagg agggtggtgg gtggggtggg gcatgtttcc caccagccct gccctgtccg

9954241

atcagTGAGA CCCGCCTGGT AGAGGTGCTG GAGGGTGTGT GCAGCAAGTC AGACTTCGAG

9954301

TGCCACCGCC TGCTGGAGCT GAGTGAGGAG CTGGTGGAGA GCTGGTGGTT TCACAAgtga

E3Rseq

9954361

gtggcaaagg gccttccctg gaagtgggtc acaggtgagg cctggtgata aggcctgatt

E3R

9954421

tggccgagaa gcaggggggt gcatgctggg gcccatgtcc tggttgtgct ccttccaaac

9954481

ccaggtctgc taagaacttg ccgggggact tgcgctccac tttgagcctc agtttaccct

Exon 3

E4Rseq
E4R

9954541

tctgccaaat ggggaaaggg cattggtcag atggcctttt gggtcttatg tccaagctgg

E4F

9954601

gttgaatcac agattcaggc atgggggaat gggaacagca cttatgacac tatctcagca

E4Fseq

9954661

cctcctcccc acctccctcc accctgcccc tgcctcagGC AGCAGGAGGC CCCGGACCTC

9954721

TTCCAGTGGC TGTGCTCAGA TTCCCTGAAG CTCTGCTGCC CCGCAGGCAC CTTCGGGCCC

9954781

TCCTGCCTTC gtgagttttt aagttgctct tggggatggg aggggaccac cgagtccagg

9954841

gatccagtcc tggctctgtc cctagttcgc tgtgtgaact caggctactc agataaactt

9954901

ctctggacct cagttcttgc ctgcctgaca gggctgggga gatgggcaaa tcagtgggga

9954961

aaggcttgga gaaagcacag gggctagact gagtcatatg cagtatagtt atcatcatgt

9955021

actaaagaaa tgatagactt cccagcccct tcatttccca tgccagatcg gactatggta

9955081

ccttcctggg gaggggcggg tgctgacctg gagcctccat gatcgccatc catcctcaca

9955141

cacagtcctg gcacaagagc tgaacttact accagcctct tttagagcag tctttcctga

9955201

agctacagat aaagagctag ctacaaagat ggcaaattca gtctttgtaa aagaaaatat

9955261

tggctgggcg cggtggctca cacctgtaat cccaacactt tgggaggctg cggtgggtgg

9955321

atcatgaggt caggagatcg agaccatcgt ggctatcatg gtgaaacacc gtctctacta

9955381

aaaaatacaa aaaattagcc gggcatggtg gcgggcgcct ctagtcccag ctactctgga

9955441

ggctgaggca gaagaatggc atgaacccgg caggcggagc ttgcagtgag ccgagatcat

9955501

gccactgcac tccagcctgg gcgacagagc gagactctgt ctcaaaaaaa aaaaagaaaa

9955561

tatttggtcc agtggctcgt acctgtaaac ccagcacttt gggaggctga ggcaggagga

9955621

tcacttgagg ccaggagttt gagagaccag cctgggtagt agagcaagac cctgtctctt

9955681

aaaaaaaaaa tagtggggca tggtagtgca gcctgttgtt cccctaggct gaggtgggag

9955741

gattgcttga gcccaggagt tcgaagctgc agtgagctat gatcatgtca ttgcctggga

9955801

aacagagcga gaccctgtca ctaaaaataa ataaataaat aaataaataa ataaataaat

9955861

aaataaataa aaggtctgta aaatctaatt gttccacaag aggaaattgg ttaagtaaat

9955921

gtcagtttta tgacaaaata ttatgtcatt aaaattaatt ttcttctcca aaaatgttta

9955981

ctgatatgca gagcagaaaa tattatcttg ttttttttgt ttttttgtct tttttattga

9956041

tcattcttgg gtgtttctcc cagaggggga tttggcaggg tcataggaca atagtggagg

9956101

gaaggtcagc agataaacaa gtgaacaaag gtctctggtt ttcctaggca gaggaccctg

9956161

cggccttccg cagtgtttgt gtccctgggt acttgagatc aaggagtggt gatgactctc

9956221

aaccagcatg ctgccttcaa gcatctgttt aacaaagcac atcttgcacc gcccttaatc

9956281

catttaaccc tgagtggaca cagcacatgt ttcagagagc acagggttgg ggataaggtc

9956341

atagatcaac aggatcccaa ggcagaagaa tttttcttag tacagaacaa aatgaaaagt

9956401

ctcccgtgtc tacttctttc tacacagaca cagcaaccat ccgatttctc agtgttttcc

9956461

ccacctttcc cccttttcta ttccacaaaa ccgccattgt catcctggcc cgttctcaat

9956521

gagctgttgg gtacacctcc cagacggggt ggtggccggg cagaggggct cctcacttcc

9956581

cagtaggggc agccgggcag aggcgcccct cacctcccgg acggggcggc tggccgggcg

9956641

gggggctgac cccctcacct ccctcccgga cgggctggct gcccggcgga gacacttctc

9956701

acttcccaga cggggcggct gccgggcgga ggggctcctc acttctcaga cagggcggcc

9956761

gggcagagac gctcctcacc tcccagacgg ggtcgcggcc gggcagagac gctcctcact

9956821

tcctagatgg gatggcggcc gggcagagac gctcctcact ttccagactg ggcagcctgg

Exon 4

59

9956881

cagagaggct cctcatatcc cagacgatgg gccgccaggc agagacgctc ctcacttccc

9956941

agacggggtg gtggccgggc agaggctgca atctcggcac tttgggaggc caaggcaggc

9957001

ggctgggagg tggaggttgt agcgagccga gatcacgcca ctgcactcca gcctgggcac

9957061

cattgagcac tgagtgaacg agactccgtc tgcaatcccg gcacctcggg aggccgaggc

9957121

tggcggatca ctcgcgttta ggagctggag accggcccgg ccaacacagc gaaaccccgt

9957181

ctccaccaaa aaaatacgaa aaccagtcag gcgtggtggc gcgcgcctgc aatcgcaggc

9957241

actcggcagg ttgaggcagg agaatcaggc agggaggttg cagtgagccg agatggcagc

9957301

agtacagtcc agcttcagct tggcatcaga gggagaccgt gtaaagagag ggagagggag

9957361

accatgggga gagggagagg gaggccatgg ggagagggag agggaaaggg ggagggggag

9957421

gggagggggg gagggaggga aggcaaggga gagggagagg gagagggaga aaatattatc

9957481

ttgtatatca aggttgtata gatgacctca cctggtttgg tgtcttccca cagCCTGTCC

9957541

TGGGGGAACA GAGAGGCCCT GCGGTGGCTA CGGGCAGTGT GAAGGAGAAG GGACACGAGG

9957601

GGGCAGCGGG CACTGTGACT GCCAAGCCGG CTACGGGGGT GAGGCCTGTG GCCAGTGTGG

9957661

CCTTGGCTAC TTTGAGGCAG AACGCAACGC CAGCCATCTG GTATGTTCGG gtaggtagcc

E5-6F
E5-6Fseq
Exon 5

18seq
E5Rseq

E6Rseq
E5-6R

9957721

aaaaggtgtg gcactgggca ggggcagatg gggcacctgc ctgcccatcc tcatgctgcc

9957781

cccattccac ccagCTTGTT TTGGCCCCTG TGCCCGATGC TCAGGACCTG AGGAATCAAA

9957841

CTGTTTGCAA TGCAAGAAGG GCTGGGCCCT GCATCACCTC AAGTGTGTAG gtaagtgggg

9957901

ccctagctag gtctgggaag atggtcaggg gcctgggctt ggtcctttat tctctcaaca

9957961

caagcctggg ctagactagc ctagtctcca ccttcatgga gatctcaacc tggctgggaa

9958021

ggcagaaaag taaccagata cttacagtcc agtacacagg tactgtgtag tatagtccct

9958081

gtgtacagtg agagatgcct ctgatctagt tcagtggaag tggtgatggg gaatcaggaa

9958141

aggcttcttg gaggaggcgt tactttggcc aagtcctaaa aattgaggaa ggggctgggc

9958201

gcggtggctc acgcctgtaa tcccagcact ttgggaggcc aaggcgggca gatcatgaga

9958261

tcaggagatc gagaccatcc tggctaacat ggtgaaaccc tgtctcaact aaaaatacaa

9958321

aaaattagct gggcgtggtg gcgggtgcct gtagtcccag ctactcagga ggctgaggca

9958381

ggagaagggc atgaacctgg gaggcggagc ttgcagtgag ccgagatcgc accactgcac

9958441

tccagtctgg gcaacagagg gagactccat ctcaaaaaaa aaaaaaaaaa aaaaaaaaaa

9958501

tgaggaaggg ttggctagga gaatgaggac actgaacttg gggtcaggaa acctgggttc

9958561

aagacttggt ttggtcccag cctagccact tatatagact aaagtaaagg ctaagctgct

9958621

gtaacaaaaa tccccaaaag actgtggctt aaagagtata gaggttggct gggtgtggta

9958681

gctcactcac gcctctaatc ccagcacttt gagaggctga agtggggtgg atcacctgag

9958741

gtcaggagtt cgagaccagc ctggccaaca tggcaaaacc ctgtctgtac taaaaataca

9958801

aaaatttagc caggcatggt ggcaggtgcc tgtaatccca gctactcggg aggcagaggc

9958861

aggagagtcg cttgaatcca ggaggcagag gttgcagtga gccaagatca caccattgca

9958921

ctctagcctg ggtgacaaga gcgaaactcc atctcaaaaa aaaaaaaaag aatctagagg

9958981

gtagaggttt attttttttt atcatattac agtcccaaag tgagtagtcc aggctggcag

9959041

gggagctctg ctagtcataa tcattccagt acccagatta ttcctgtaac ttactgcaca

9959101

atcatcccct tgggcgttgt ctgcatggtt gaagctgagt cctgggcatc tctgtgtccc

9959161

acatgccagc actcaggaag ggagaaggga aagaaagtgc attgaggagt ccaagcattg

9959221

ttttaagacc aagctaacgg tggagctcat cactcctgtt tacatcctgt tggccagaac

9959281

tcaatcacag ggacacactt agcttcaaga caggttggca aatgtggtct ctggctgggc

9959341

agcctgaagt ccagctagtc tgcttctgtg ttggtagaca gcttgcagtc tctgccatac

9959401

catttaatcc caggcaagac cattccccaa cggctctggc ttcagcttcc ctactaaata

9959461

gggattgaaa ttctcaccct gctcacctct ctgcagACAT TGATGAGTGT GGCACAGAGG

9959521

GAGCCAACTG TGGAGCTGAC CAATTCTGCG TGAACACTGA GGGCTCCTAT GAGTGCCGAG

Exon 6
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E8Rseq

9959581

gtcagtgtct acttctgcag aggaggggac gtgaggagtg gaggaagagc tgctccacac

9959641

ctgtccctcc aaaccttccc cttctcaggc ttcagagcac ccccaggcct ccgcttctgg

9959701

agcgtggctc ccctgggcct aggtgcacat ctcaccctca tctttctctc ctctctccag

9959761

ACTGTGCCAA GGCCTGCCTA GGCTGCATGG GGGCAGGGCC AGGTCGCTGT AAGAAGTGTA

9959821

GCCCTGGCTA TCAGCAGGTG GGCTCCAAGT GTCTCGgtga gtctcctgct gatgggacac

9959881

aggcacctgg gagtgcctca cccagcatga atggtgaaga ggctggaata tgggcaggtg

9959941

ggggaaggaa gggtggaatg ttgcctgggc aagggcagag gggagtgttg agagatggac

9960001

aagatggagt cagggtgctg ggtggggggc cctagcagga ctctgacccc tccctcccct

9960061

caagATGTGG ATGAGTGTGA GACAGAGGTG TGTCCGGGAG AGAACAAGCA GTGTGAAAAC

9960121

ACCGAGGGCG GTTATCGCTG CATCTGTGCC GAGGGCTACA AGCAGATGGA AGGCATCTGT

E9Rseq

9960181

GTGAAGGAGC AGATCCCAGg tgagccctgg ggcgggagag gggaggtcct cattcaaaga

E7-8-9R

9960241

gaaggcaggc aagccccttc cccaggtagc agtggcagct ccaggccctg ccccatccct

10seq

8seq
E10R

9960301

actgccaccc agccccctgg aggctgcact gagaccgggc tctacatctg atctccaggt

9960361

tggctctcag cagccttata ccttccaggg tacaaaggga atcagacctg gcatcaaatc

9960421

agtctgcctc cttaacctgt ttcctcatct atccaatggg accagtgttt gccctggcct

9960481

gctgagagct gtcctaggcc gggggtgtgg tgagatgcag ggtaatcaca acgatgatgg

9960541

cagggaccat ttccccagca attactgtgt cagatgctgt tctagGTGCA TTCCCCATCT

9960601

TAACTGATTT AACCCCTGAA ACAACCCGAC GCTGGAAGTT GGGTTCTCAT CCCCACTCTA

9960661

CATATGTAAA AATGAAGATG CAGAGAGATG AAGCTACTTT CCCAGGGCTA TATGGCAAGC

9960721

AAGTCGCAAA GCTGGGATCC CAATCCAGAC AGTCTGACCG TGGAACGAGA CTCATACACg

9960781

taataaatgc tctgccccca acttgtccac cacatggcct tggcaagtcc aaccccttta

9960841

cctctctgag cctcactttc ccatttagtg agacagggat ggtaactgcc ccttgcaggg

9960901

tggttttgag cagtaaatgt agtgtgcctg gcttgctggg caggcctggt ggccatgatg

9960961

atcaggtgtg tgggagttct ggggagactc caagaactac caggaacagg gatacgagtg

9961021

ccaggctgca tctcttgctc ctctgcagAG TCAGCAGGCT TCTTCTCAGA GATGACAGAA

9961081

GACGAGTTGG TGGTGCTGCA GCAGATGTTC TTTGGCATCA TCATCTGTGC ACTGGCCACG

9961141

CTGGCTGCTA AGGGCGACTT GGTGTTCACC GCCATCTTCA TTGGGGCTGT GGCGGCCATG

9961201

ACTGGCTACT GGTTGTCAGA GCGCAGTGAC CGTGTGCTGG AGGGCTTCAT CAAGGGCAGA

9961261

TAATCGCGGC CACCACCTGT AGGACCTCCT CCCACCCACG CTGCCCCCAG AGCTTGGGCT

9961321

GCCCTCCTGC TGGACACTCA GGACAGCTTG GTTTATTTTT GAGAGTGGGG TAAGCACCCC

9961381

TACCTGCCTT ACAGAGCAGC CCAGGTACCC AGGCCCGGGC AGACAAGGCC CCTGGGGTAA

9961441

AAAGTAGCCC TGAAGGTGGA TACCATGAGC TCTTCACCTG GCGGGGACTG GCAGGCTTCA

9961501

CAATGTGTGA ATTTCAAAAG TTTTTCCTTA ATGGTGGCTG CTAGAGCTTT GGCCCCTGCT

9961561

TAGGATTAGG TGGTCCTCAC AGGGGTGGGG CCATCACAGC TCCCTCCTGC CAGCTGCATG

9961621

CTGCCAGTTC CTGTTCTGTG TTCACCACAT CCCCACACCC CATTGCCACT TATTTATTCA

9961681

TCTCAGGAAA TAAAGAAAGG TCTTGGAAAG TTAAAAGGCA TCAGTCTTAC TACCTGTCCC

9961741

ACCACCCCCA CCTTAGGGAA ATGTCCTAGA ATCCTGGGAA ATTGAGGGCT TCTTTGATGG

9961801

TGAGTGGAGA AAAGATAGAG GAGAAGGTTG CCCCTGAAGT GCTGTTAGGA GAAGGAGGAT

9961861

AGAGGAATCA GCCTTAGGAG GGTTCCATGC CAGCTGTCAT TTGGCAAAGG ACCCTGGACA

9961921

GATGACTTTT GCCTCTGAAC TTCACTCTTC TCTTTCCTCA AATGGGCTTC ATAATGCTTT

9961981

CCACTCAGGC TTAACATGAG AATTAAATGA GGTGACAAAT GTGAAGACCT GGACAGTACA

9962041

CAACAGATAT TCAATAAAAG TGTGGTCGCC ATTATGACCA GAGCCTCCAA

E8Fseq

Exon 8
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Translation (NP_056328.2 and NP_001070883.1)
MAPWPPKGLVPAMLWGLSLFLNLPGPIWLQPSPPPQSSPPPQPHPCHTCRGLVDSFNKGL
ERTIRDNFGGGNTAWEEENLSKYKDSETRLVEVLEGVCSKSDFECHRLLELSEELVESWW
FHKQQEAPDLFQWLCSDSLKLCCPAGTFGPSCLPCPGGTERPCGGYGQCEGEGTRGGSGH
CDCQAGYGGEACGQCGLGYFEAERNASHLVCSACFGPCARCSGPEESNCLQCKKGWALHH
LKCVDIDECGTEGANCGADQFCVNTEGSYECRDCAKACLGCMGAGPGRCKKCSPGYQQVG
SKCLDVDECETEVCPGENKQCENTEGGYRCICAEGYKQMEGICVKEQIPESAGFFSEMTE
DELVVLQQMFFGIIICALATLAAKGDLVFTAIFIGAVAAMTGYWLSERSDRVLEGFIKGR
X
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